Phase II Study of Gefitinib in Patientswith Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression : A Gynecologic Oncology Group Study